#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Asthma Dermatitis atopic Breast cancer metastatic Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Loss of consciousness ABO haemolytic disease of newborn Waldenstrom's macroglobulinaemia Hodgkin's disease Familial amyotrophic lateral sclerosis Follicular lymphoma stage III Squamous cell carcinoma of the hypopharynx Glioblastoma multiforme Candida infection Warm autoimmune haemolytic anaemia Meningitis meningococcal Red blood cell abnormality Leukaemia Subdural haematoma Myelin oligodendrocyte glycoprotein antibody-associated disease More trials…

    Learn about Rare Diseases

    Short-bowel syndrome – Diagnostics Indolent systemic mastocytosis – Life with Disease Inclusion body myositis – Treatment Lymphangioma – Life with Disease Choroid melanoma – Trials in Disease Fragile X syndrome – Diagnostics Hereditary neuropathic amyloidosis Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Diagnostics Waldenstrom’s macroglobulinaemia refractory – Treatment Urea cycle disorder – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Sorafenib Dacomitinib Dimethyl Fumarate Lufepirsen FRUQUINTINIB Mavorixafor Obeticholic Acid Flutafuranol (18F) Ergocalciferol Bp Atropine Sulfate Monohydrate Futibatinib 177Lu-Dpi-4452 Milvexian Pervi-Neo Immunglobulin Rusfertide Naproxen Sodium Defactinib Lovotibeglogene Autotemcel Vsf1.01 More therapies…

    Learn about Your Condition

    Major depression Tricuspid valve disease Infant sedation Rhinitis allergic Stress urinary incontinence Anxiety Elderly Conjunctivitis Malformation venous Metastases to meninges Viral myocarditis Hyperparathyroidism primary Adenosquamous cell lung cancer Infection Post-acute COVID-19 syndrome More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. University Of Debrecen

University Of Debrecen

Myzoue Ziisbchw Kusia 2ky Dxhkhpzaw 4hklg Hwtytwb

Want to learn more about this study or check if you can participate? Contact us.

  • Study of human normal immunoglobulin and teclistamab for infection prevention in adults with multiple myeloma receiving B-cell maturation antigen therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Human Normal Immunoglobulin
    • Teclistamab
    Austria Czechia Denmark Germany Greece Hungary +6

  • Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • ARLOCABTAGENE AUTOLEUCEL
    • Carfilzomib
    • Cyclophosphamide
    Austria Belgium Czechia Denmark Finland France +11

  • Study of Lisaftoclax Alone or with Drug Combination for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • B-cell small lymphocytic lymphoma
    • Chronic lymphocytic leukaemia
    Investigated Drugs:
    • Acalabrutinib
    • Lisaftoclax
    • Zanubrutinib
    Hungary Poland

  • Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

    Recruiting

    3 1
    Investigated Diseases:
    • Acute myocardial infarction
    Investigated Drugs:
    • Selatogrel
    Austria Belgium Bulgaria Croatia Czechia Denmark +17

  • Study on the Safety and Effectiveness of Upadacitinib and Dupilumab for Children Aged 2 to 12 with Moderate to Severe Atopic Dermatitis

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Dupilumab
    • Upadacitinib
    Austria Bulgaria Croatia France Germany Hungary +6

  • Efficacy and safety of efgartigimod alfa in adults with Sjögren’s disease‑associated sensorimotor or sensory polyneuropathy: a phase 2 randomized placebo‑controlled study

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Sjogren’s syndrome
    Investigated Drugs:
    • Efgartigimod Alfa
    Belgium France Germany Hungary Lithuania Portugal +1

  • Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Bortezomib
    • Carfilzomib
    • Everolimus
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Efficacy and Safety of Intranasal Cenegermin in Adults with Non‑Arteritic Anterior Ischemic Optic Neuropathy (NAION)

    Not yet recruiting

    2 1
    Investigated Drugs:
    • Cenegermin
    Belgium Denmark France Germany Hungary Italy +3

  • Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • HUMAN IGG1 KAPPA MONOCLONAL ANTIBODY AGAINST FOLR1 CONJUGATED TO 1-[(2R,3R,4R,5S,52S)-1,2,3,4,5-PENTAHYDROXY-52-{[(2S)-1-{[(2S)-5-CARBAMOYLAMINO-1-OXO-1-{3-[({[(1S,9S)-9-ETHYL-5-FLUORO-9-HYDROXY-4-METHYL10,13-DIOXO-2,3,9,10,13,15-HEXAHYDRO-1H,12HBENZO[DE]PYRANO[3′,4′:6,7]INDOLIZINO[1,2-B]QUINOLIN-1-YL]CARBAMOYL}OXY)METHYL]ANILINO}PENTAN-2-YL]AMINO}-3-METHYL-1-OXOBUTAN-2-YL]CARBAMOYL}-7-[(2S,3R,4R,5R)-2,3,4,5,6-PENTAHYDROXYHEXYL]-46,54-DIOXO10,13,16,19,22,25,28,31,34,37,40,43-DODECAOXA-7,47,53-TRIAZANONAPENTACONTAN-59-YL]-2,5-DIOXOPYRROLIDIN-3-YL
    Austria Belgium Czechia Denmark Finland France +6

  • A Phase 3 Study of Engasertib to Evaluate Safety and Effectiveness in Adults with Moderate to Severe Hereditary Hemorrhagic Telangiectasia

    Not yet recruiting

    3 1
    Investigated Diseases:
    • Hereditary haemorrhagic telangiectasia
    Belgium Bulgaria France Germany Hungary Italy +3
Previous Page
1 … 17 18 19 20 21 … 52
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!